Yaron Werber
Stock Analyst at TD Cowen
(0.89)
# 3,652
Out of 4,829 analysts
43
Total ratings
31.03%
Success rate
-20.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yaron Werber
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWTX SpringWorks Therapeutics | Downgrades: Hold | $66 → $47 | $46.12 | +1.91% | 1 | Apr 29, 2025 | |
| ONC BeiGene | Reiterates: Buy | $334 | $232.54 | +43.63% | 1 | Apr 24, 2025 | |
| FBRX Forte Biosciences | Initiates: Buy | n/a | $6.38 | - | 1 | Jan 21, 2025 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | n/a | $20.36 | - | 1 | Dec 20, 2024 | |
| SEPN Septerna | Initiates: Buy | n/a | $7.08 | - | 1 | Nov 19, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $160 → $153 | $156.40 | -2.17% | 5 | Nov 15, 2024 | |
| BNTX BioNTech SE | Maintains: Hold | $132 → $122 | $96.75 | +26.10% | 5 | Nov 6, 2024 | |
| UPB Upstream Bio | Initiates: Buy | n/a | $9.55 | - | 1 | Nov 5, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $61 → $73 | $36.63 | +99.29% | 2 | Oct 21, 2024 | |
| EXEL Exelixis | Maintains: Buy | $27 → $34 | $37.10 | -8.36% | 2 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $59 | $33.58 | +75.70% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $67 | $32.74 | +104.64% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $9.79 | - | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.89 | - | 1 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.16 | - | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.00 | - | 2 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $19.87 | - | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $612 → $641 | $561.09 | +14.24% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.39 | - | 1 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $25 | $0.31 | +8,096.72% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.72 | - | 2 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $38 | $19.84 | +91.53% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.47 | - | 3 | Apr 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.99 | - | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.00 | - | 1 | Oct 26, 2021 |
SpringWorks Therapeutics
Apr 29, 2025
Downgrades: Hold
Price Target: $66 → $47
Current: $46.12
Upside: +1.91%
BeiGene
Apr 24, 2025
Reiterates: Buy
Price Target: $334
Current: $232.54
Upside: +43.63%
Forte Biosciences
Jan 21, 2025
Initiates: Buy
Price Target: n/a
Current: $6.38
Upside: -
Dianthus Therapeutics
Dec 20, 2024
Initiates: Buy
Price Target: n/a
Current: $20.36
Upside: -
Septerna
Nov 19, 2024
Initiates: Buy
Price Target: n/a
Current: $7.08
Upside: -
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $160 → $153
Current: $156.40
Upside: -2.17%
BioNTech SE
Nov 6, 2024
Maintains: Hold
Price Target: $132 → $122
Current: $96.75
Upside: +26.10%
Upstream Bio
Nov 5, 2024
Initiates: Buy
Price Target: n/a
Current: $9.55
Upside: -
Ultragenyx Pharmaceutical
Oct 21, 2024
Maintains: Buy
Price Target: $61 → $73
Current: $36.63
Upside: +99.29%
Exelixis
Oct 21, 2024
Maintains: Buy
Price Target: $27 → $34
Current: $37.10
Upside: -8.36%
Jul 23, 2024
Maintains: Buy
Price Target: $54 → $59
Current: $33.58
Upside: +75.70%
Jul 15, 2024
Maintains: Buy
Price Target: $71 → $67
Current: $32.74
Upside: +104.64%
Mar 26, 2024
Upgrades: Buy
Price Target: n/a
Current: $9.79
Upside: -
Mar 18, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.89
Upside: -
Mar 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.16
Upside: -
Jan 31, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $5.00
Upside: -
Dec 20, 2023
Initiates: Outperform
Price Target: n/a
Current: $19.87
Upside: -
Dec 12, 2023
Maintains: Outperform
Price Target: $612 → $641
Current: $561.09
Upside: +14.24%
Oct 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.39
Upside: -
Feb 28, 2023
Maintains: Market Perform
Price Target: $15 → $25
Current: $0.31
Upside: +8,096.72%
Nov 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $13.72
Upside: -
May 2, 2022
Initiates: Market Perform
Price Target: $38
Current: $19.84
Upside: +91.53%
Apr 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.47
Upside: -
Nov 30, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.99
Upside: -
Oct 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.00
Upside: -